113. Muscular dystrophy Clinical trials / Disease details
Clinical trials : 646 / Drugs : 471 - (DrugBank : 105) / Drug target genes : 59 - Drug target pathways : 170
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | JPRN-UMIN000016092 | 2014/12/31 | 31/12/2014 | Analysis of the effects of animal fat free diet and aspirin for prostaglandins in patients with myotonic dystrophy | Analysis of the effects of animal fat free diet and aspirin for prostaglandins in patients with myotonic dystrophy - Animal fat free diet and aspirin in patients with myotonic dystrophy | myotonic dystrophy | 1st stage (1w): animal fat free diet 2nd stage (1w): animal fat free diet and aspirin (330mg/day) | National Hospital Organization Toneyama National Hospital | Graduate school of engineering Osaka University | Complete: follow-up complete | Not applicable | Not applicable | Male and Female | 10 | Not applicable | Japan |
2 | JPRN-UMIN000009307 | 2012/11/08 | 10/11/2012 | Inhibition of prostagrandin synthesis for the treatment of Duchenne musclar dystrophy | Inhibition of prostagrandin synthesis for the treatment of Duchenne musclar dystrophy - Inhibition of prostagrandin synthesis for the treatment of Duchenne musclar dystrophy | Duchenne muscular dystrophy | oral adm,inistration of aspirin | Kobe University Graduate School of Medicine | NULL | Complete: follow-up complete | 5years-old | Not applicable | Male | 6 | Phase 1,2 | Japan |